---
title: "3 Reasons to Buy Novo Nordisk Stock Right Now"
description: "The pharmaceutical leader is gradually laying the groundwork for a strong rebound."
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/258887879.md"
published_at: "2025-09-25T12:37:14.000Z"
---

# 3 Reasons to Buy Novo Nordisk Stock Right Now

> The pharmaceutical leader is gradually laying the groundwork for a strong rebound.

The pharmaceutical leader is gradually laying the groundwork for a strong rebound.

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 高盛：诺和诺德定价压力被市场过度定价，口服 Wegovy 将是扭转信心的关键 | 高盛称，当前股价已完全消化 2026 财年最悲观预期。市场低估了 Medicare 放开的销量潜力和口服版 Wegovy 的收入前景。口服 Wegovy 上市表现强劲，已开出 5 万张处方，其中 9 成为自费需求，显示刚性市场潜力，将成为扭 | [Link](https://longbridge.com/en/news/275095024.md) |
| 诺和诺德公司首席财务官 Karsten Munk Knudsen 出售了价值超过 830 万丹麦克朗的股票 | 诺和诺德公司（Novo Nordisk A/S）宣布，首席财务官卡斯滕·穆克·克努森（Karsten Munk Knudsen）于 2026 年 2 月 10 日以每股 DKK 315.60 的价格出售了 26,246 股，交易总额为 DK | [Link](https://longbridge.com/en/news/275652909.md) |
| Vanda 制药｜8-K：2025 财年 Q4 营收 57.22 百万美元不及预期 |  | [Link](https://longbridge.com/en/news/275657004.md) |
| 诺和诺德公司将在其爱尔兰工厂生产 Wegovy | 诺和诺德公司将在爱尔兰工厂生产 Wegovy | [Link](https://longbridge.com/en/news/275789396.md) |
| Vanda 制药｜10-K：2025 财年营收 2.16 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/275753219.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.